Axicabtagene ciloleucel
Medication to treat large B-cell lymphoma / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Yescarta?
Summarize this article for a 10 year old
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment.[8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow.[9] Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.[9]
Clinical data | |
---|---|
Trade names | Yescarta |
Other names | KTE-C19, Axi-cel |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618003 |
License data | |
Pregnancy category | |
Routes of administration | Intravenous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
UNII | |
KEGG |
Due to CD19 being a pan-B cell marker,[10] the T-cells that are engineered to target CD19 receptors on the cancerous B cells[9] also influence normal B cells, except some plasma cells.[11]